Conditions associated with PSVD: impact on prognosis and treatment – Paris PSVD Meeting

Value of the Information & Strength of the Argument

The presentation provides valuable information on the spectrum of conditions associated with PSVD, synthesizing recent cohort data and highlighting the prognostic significance. The argumentation is solid, drawing on large European and Chinese cohorts, and clearly explains the clinical implications. The speaker is careful to distinguish between established associations and those requiring further investigation. The discussion of treatment impact, though based on limited case series, is well-reasoned and acknowledges the need for more robust evidence. The Q&A adds depth, addressing concerns about drug causality and the need for systematic screening.

Scientific Rigor, Source Quality, Title Accuracy

The presentation demonstrates scientific rigor by referencing recent peer-reviewed studies (e.g., Maggas et al., Chinese cohorts) and ongoing research initiatives. The speaker clearly distinguishes between evidence levels, noting that treatment impact data are based on case reports and case series. The title accurately reflects the content. The sources cited are appropriate and credible, though the talk itself is an expert opinion rather than a systematic review. The Q&A session further enhances the scientific discussion.

The title accurately reflects the content, which focuses on associated conditions of PSVD, their prognostic impact, and treatment implications.

8/10

Presentation by a recognized expert in the field, based on recent cohort studies and case series, with clear references to ongoing research. However, the talk is largely based on expert opinion and limited case reports, and some claims lack robust evidence.

Markers derived by PSI from the transcript: the creator did not define chapters.

• 00:00Introduction and overview of the talk's focus on associated conditions in PSVD.
• 01:00Presentation of the European cohort study (Maggas et al.) showing two-thirds of PSVD patients have an associated condition, impacting prognosis.
• 03:00Discussion of immunodeficiencies, particularly common variable immunodeficiency, and its association with PSVD.
• 05:00Mention of immune-mediated disorders, including antiphospholipid syndrome, and ongoing studies on PSVD in systemic sclerosis.
• 07:00Review of drug and toxin exposures, including didanosine, thiopurines, and oxaliplatin, and their link to PSVD.
• 09:00Discussion of infections, particularly chronic hepatitis B and HIV, as potential associated conditions.
• 11:00Overview of hematological disorders, such as myeloproliferative neoplasms, and their association with portal vein thrombosis.
• 13:00Genetic disorders and familial aggregation in PSVD, with emphasis on pediatric cohorts and telomere biology.
• 15:00Impact of treating associated conditions: case series on drug discontinuation (e.g., didanosine, thiopurines) leading to improvement.
• 17:00Further examples of treatment impact: PNH treated with eculizumab and cystic fibrosis with CFTR modulators improving portal hypertension.

• European cohort study on PSVD (Maggas et al.) — Cited as the European cohort with nearly 600 patients, showing associated conditions in two-thirds and impact on prognosis.
• Chinese cohort study on PSVD — Cited as a study of 128 patients showing associated conditions linked to a more portal hypertensive phenotype.
• Dutch retrospective study on thiopurine-induced NRH — Cited as a study of 43 IBD patients with NRH, showing improvement after drug discontinuation.
• Study on 6-thioguanine and NRH — Cited as a paper from ~20 years ago with 24 IBD patients, showing HVPG normalization after stopping treatment.

• European cohort study on PSVD (Maggas et al.) — Supports the prevalence of associated conditions and their impact on prognosis.
• Chinese cohort study on PSVD — Confirms the association with portal hypertensive phenotype.

• Question from audience regarding drug-induced PSVD — A clinician expressed doubt about thiopurine-induced PSVD, suggesting it may be immune-mediated rather than direct drug toxicity.